Valuation: Neuland Laboratories Limited

Market Cap 247B 2.6B 2.32B 2.15B 1.95B 3.67B 3.73B 25.77B 10.13B 129B 9.76B 9.56B 412B P/E 2027 *
51.6x
P/E 2028 * 39.5x
Enterprise Value 249B 2.63B 2.34B 2.17B 1.97B 3.71B 3.77B 26.05B 10.24B 130B 9.87B 9.66B 417B EV / Sales 2027 *
10.3x
EV / Sales 2028 * 8.54x
Free-Float
62.26%
Yield 2027 *
0.12%
Yield 2028 * 0.16%
1 day-2.41%
1 week-6.56%
Current month-10.14%
1 month-15.96%
3 months+4.35%
6 months+25.64%
Current year+26.56%
1 week 19,117.4
Extreme 19117.4
20,542.4
1 month 19,117.4
Extreme 19117.4
23,030.95
Current year 11,500
Extreme 11500
24,235.05
1 year 11,500
Extreme 11500
24,235.05
3 years 3,612.05
Extreme 3612.05
24,235.05
5 years 965.85
Extreme 965.85
24,235.05
10 years 247.3
Extreme 247.3
24,235.05
Manager TitleAgeSince
Chief Executive Officer 47 01/04/2026
Director of Finance/CFO - 23/11/2022
Chief Tech/Sci/R&D Officer - 01/03/2023
Director TitleAgeSince
Director/Board Member 50 01/01/2002
Chairman 82 07/01/1984
Director/Board Member 47 01/03/2007
Change 5-day change 1-year change 3-year change Capi.($)
-2.41%-6.56%+18.02%+362.36% 2.66B
-1.33%+4.88%+54.50%+109.94% 1,120B
-0.69%-3.77%+31.35%+66.62% 616B
-0.96%+0.55%+23.13%+94.26% 504B
+0.24%+5.58%+33.98%+59.40% 367B
-1.59%-1.25%+69.39%+43.02% 360B
-0.40%+3.53%+19.17%+46.55% 288B
-0.37%+3.11%-1.26%+18.23% 258B
-1.75%+1.76%+42.21%+51.44% 234B
-2.00%+1.75%+24.64%+95.14% 194B
Average -1.13%+1.51%+31.51%+94.70% 394.36B
Weighted average by Cap. -0.99%+2.42%+37.88%+75.71%

Financials

2027 *2028 *
Net sales 24.18B 255M 227M 211M 191M 359M 365M 2.53B 993M 12.64B 957M 937M 40.4B 29.06B 306M 273M 253M 230M 432M 439M 3.04B 1.19B 15.19B 1.15B 1.13B 48.55B
Net income 4.8B 50.61M 45.11M 41.79M 38M 71.3M 72.47M 501M 197M 2.51B 190M 186M 8.02B 6.26B 66.08M 58.9M 54.56M 49.61M 93.09M 94.62M 654M 257M 3.27B 248M 243M 10.47B
Net Debt 2.69B 28.37M 25.29M 23.42M 21.3M 39.97M 40.62M 281M 110M 1.41B 106M 104M 4.49B 1.58B 16.64M 14.84M 13.74M 12.5M 23.45M 23.83M 165M 64.82M 825M 62.44M 61.14M 2.64B
Projected Income Statement - Annual - Neuland Laboratories Limited
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
19/10/26 ₹19,224.50 -2.41% 4,956
16/10/26 ₹19,699.70 -1.22% 1,301
15/10/26 ₹19,942.80 -1.27% 2,966
14/10/26 ₹20,200.35 -0.74% 1,647
13/10/26 ₹20,351.90 -1.08% 3,537
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Neuland Laboratories Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
19,224.50INR
Average target price
24,678.50INR
Spread / Average Target
+28.37%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Neuland Laboratories Limited
  1. Stock Market
  2. Stocks
  3. NEULANDLAB Stock